AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02344719 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HVPG Measurement day 28
Description: On day 1 (baseline) and day 28 HVPG measurement will be performed
Study NCT02344719 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: HVPG Measurement day 28
Description: On day 1 (baseline) and day 28 HVPG measurement will be performed
Study NCT02344719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 6g per day per oral for 28 days
Description: Placebo to Taurin 6g per day per oral for 28 days
Study NCT02767895 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Participants will receive an informational DVD, a pedometer, an incentive spirometer and access to the program website to help promote healthful behaviors and improved well-being in the days leading up to surgery.
Study NCT06048432 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy + telephysiotherapty
Description: Patients assigned to the telephyisiotherapy (TP) group will carry out a half-hour session of conventional therapy, plus a 1-hour session of physical exercise, which will be carried out through the administration of tutorial videos, telephone instructions or by email.
Study NCT06048432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy + telephysiotherapty
Description: Patients assigned to the telephyisiotherapy (TP) group will carry out a half-hour session of conventional therapy, plus a 1-hour session of physical exercise, which will be carried out through the administration of tutorial videos, telephone instructions or by email.
Study NCT00278889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2171
Description: oral tablet
Study NCT00278889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: intravenous infusion
Study NCT00278889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: intravenous infusion
Study NCT00278889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: intravenous infusion
Study NCT00278889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: intravenous infusion
Study NCT00278889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: intravenous infusion
Study NCT00278889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: intravenous infusion
Study NCT00278889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: intravenous infusion
Study NCT04353765 — intervention group
Intervention type: DRUG
Intervention: Cabozantinib monotherapy
Description: Intervention description (FDA Label): kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma (RCC).
Study NCT04353765 — intervention group
Intervention type: DRUG
Intervention: All authorized TKI monotherapies in advanced RCC per FDA label in advanced RCC
Description: As per authorized FDA label in advanced RCC
Study NCT04549714 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High AI in paroxysmal atrial fibrillation
Description: Patients with paroxysmal AF will receive pulmonary vein vestibule ablation with high AI value, the AI target value for the front wall and the top wall is 550, and the rear wall and the lower wall are 400.
Study NCT04549714 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Middle AI in paroxysmal atrial fibrillation
Description: Patients with paroxysmal AF will receive pulmonary vein vestibule ablation with middle AI value, the AI target value for the front wall and the top wall is 500, and the rear wall and the lower wall are 350.
Study NCT04549714 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low AI in paroxysmal atrial fibrillation
Description: Patients with paroxysmal AF will receive pulmonary vein vestibule ablation with low AI value, the AI target value for the front wall and the top wall is 450, and the rear wall and the lower wall are 300.
Study NCT06050473 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve-sacrificing procedure
Description: Surgical fixation of the clavicle fracture will be performed through a horizontal incision over the clavicle. During the incision and soft tissue dissection, the surgeon will not attempt to identify the supraclavicular nerve branches. Instead, the surgeon will cut the nerve branches during the dissection.
Study NCT06050473 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve preserving procedure
Description: Surgical fixation of the clavicle fracture will be performed through the same horizontal incision over the clavicle. The surgeon will attempt to dissect out, identify and preserve all branches of the supraclavicular nerve throughout the fracture reduction, fixation and closure.
Study NCT04193449 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: colonoscopy
Description: colonoscopy procedure
Study NCT01861691 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open surgery
Description: Conventional technique
Study NCT03986827 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cool Kids Anxiety Program - Social Enhanced
Description: Specific G-CBT intervention for adolescents with social anxiety disorder
Study NCT03986827 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cool Kids Anxiety Program
Description: Generic G-CBT intervention for adolescents with anxiety disorders
Study NCT01850186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual yellow Laser
Description: Patients will receive treatment by stabilized kilnman trio for four weeks (one application per day). Patient will receive 4 treatments by Dual yellow Laser on the hemi-face (side determinated by randomisation, split body study) at weeks 4, 6, 9 and 12.
Study NCT01850186 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Stabilized kilnman trio
Description: The stabilized kilnman trio will be prescribed for one month at inclusion (all over the face, one application per day), and on the half of the face not treated by laser at weeks 4, 8 and 12 (one application per day).
Study NCT01963286 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ICD with enhanced SVT discriminators
Description: ICD will be programmed to uniform device settings with enhanced SVT discrimintators enabled.
Study NCT04308226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: The navigator's principal role is to guide participants through the lung cancer screening (LCS) process. The navigator will work within the existing Boston Health Care for the Homeless (BHCHP) clinical structure and collaborate with participants' primary care providers (PCPs) to facilitate LCS low-dose computed tomography (LDCT) referral, completion, and timely follow-up by addressing participants' barriers to LCS completion and enhancing participants' self-efficacy. The navigator's secondary role is to offer brief tobacco counseling for participants who currently smoke.
Study NCT03141866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention 1: Move It Or Lose It (MIOLI)
Description: An established chair-based physical activity programme for older adults.
Study NCT03141866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention 2: Machine-based resistance training intervention
Description: Specialised, chair-based, pneumatic resistance training equipment for older adults.
Study NCT01772758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BH4 5mg
Description: Kuvan® or sapropterin dihydrochloride is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4). Subjects received an oral dose of 5 mg/kg of Kuvan® (Biomarin Pharmaceuticals Inc.)
Study NCT01772758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BH4 20mg
Description: Kuvan® or sapropterin dihydrochloride is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4). Subjects received an oral dose of 20 mg/kg of Kuvan® (Biomarin Pharmaceuticals Inc.)
Study NCT01772758 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidant Cocktail
Description: Vitamin C (1000 mg) , Vitamin E (600 IU) , and alpha-lipoic acid (600 mg). all BID
Study NCT03587389 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix vaccine
Description: In this study, the 1st dose of Rotarix vaccine will be administered when infants are at ages between weeks 8-9 and the 2nd dose is 28-37 days after the 1st dose, which means that there is an interval of 28-37 days or 4-5 weeks between doses. A reminding call will be set at about 4 weeks after the 1st dose to remind parents to bring their children back to Hung Vuong Hospital for the 2nd dose of Rotarix to ensure the completion of the 2nd dose of Rotarix vaccine.
Study NCT02636543 — intervention group
Intervention type: OTHER
Intervention: Questionnaire after the reading of letter B.
Description: Oral questionnaire after the reading of letter B.
Study NCT02636543 — intervention group
Intervention type: OTHER
Intervention: Questionnaire after the reading of letters A and B
Description: Oral questionnaire after the reading of letters A and B during individual interview.
Study NCT01861691 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Description: New minimum invasive technique
Study NCT04324099 — intervention group
Intervention type: OTHER
Intervention: Emotion Regulation Questionnaire (for children)
Description: 10-item scale designed to measure respondents' tendency to regulate their emotions in two ways: (1) Cognitive Reappraisal and (2) Expressive Suppression. Respondents answer each item on a 7-point Likert-type scale ranging from 1 (strongly disagree) to 7 (strongly agree)
Study NCT04602910 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a web-based shared decision-making tool
Description: Five major parts were developed with the use of the action research approach. The Introduction and Options (parts 1 and 2) describe the severity of the cancer treatment and infertility and the knowledge of fertility preservation, respectively. The SDM tool was designed as a step by step process (part 3) that involves the comparison of options, patient's values and preferences, their knowledge regarding infertility and options, and reaching a collective decision. The Resources (part 4) provide information on the hospitals that provide such services, and the References (part 5) list all the literature cited in the website. The results show the web-based SDM meets both the patients' and health providers' needs and helps reproductive-age patients with breast cancer make decisions on fertility preservation.
Study NCT04006223 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 11C-PIB or 18F-florbetapir PET/MR before biopsy and treatment
Description: 10-20 mCi 11C-PIB or 5-10 mCi 18F-florbetapir will be injected intravenously prior to imaging.
Study NCT03278795 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pressure support ventilation mode
Description: PSV is the sole mode of mechanical ventilation and will be used as a weaning mode in mechanically ventilated chronic obstructive pulmonary disease patients,In PSV weaning group , PS(pressure support) will be adjusted at 8 cmH2O until 2-h successful spontaneous breathing trial parameters according to ERS(European Respiratory Society) guidelines will be achieved and then patient will ex-tubated.
Study NCT03278795 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: volume support ventilation mode
Description: VSV mode could be viewed as PRVC for spontaneous breathing as it delivers a variable pressure to meet a target VT. VSV will be used as a weaning mode in mechanically ventilated chronic obstructive pulmonary disease patients,In VSV weaning group ,VT(tidal volume ) will be adjusted at 6 ml/ Kg until 2-h successful spontaneous breathing trial parameters according to ERS guidelines will be achieved and then patient will ex-tubated.
Study NCT04490213 — intervention group
Intervention type: OTHER
Intervention: Allevyn, Aquacel and Tegaderm, Mediskin
Description: Wound dressing tested earlier on donor sites, in this study scar outcome between the 3 dressing groups are compared.
Study NCT03763812 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endovascular Aneurysm Repair (EVAR)
Description: The following blood samples will be taken: WBC and circulating cytokines (TNF-α, Interleukin (IL)-1, 1RA, 6, 10, 18, CRP), Troponin T, HsTnT, NT-pro-BNP at these time points:~* Before induction of anesthesia~* At wound closure~* 24 hours after surgery~* 48 hours after surgery~* 1 month after surgery~* 6 months after surgery~* 12 months after surgery
Study NCT03763812 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endovascular Aneurysm Sealing (EVAS)
Description: The following blood samples will be taken: WBC and circulating cytokines (TNF-α, Interleukin (IL)-1, 1RA, 6, 10, 18, CRP), Troponin T, HsTnT, NT-pro-BNP at these time points:~* Before induction of anesthesia~* At wound closure~* 24 hours after surgery~* 48 hours after surgery~* 1 month after surgery~* 6 months after surgery~* 12 months after surgery
Study NCT01360424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Daily administration of teriparatide 20 ug s.c. for 24 months
Study NCT00817323 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dietary amino-acid depletion
Description: See detailed description
Study NCT01959178 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LD127025 MF
Description: At Visit 1, one-half of the subjects will be randomized to receive the investigational soft contact lens, after approximately one week of wearing the first lens type, the subjects will return for the 1-Week Crossover Visit (Visit 2) for an exam, and to determine if the subject remains eligible to continue in the next phase of the study with the control soft contact lens.
Study NCT01959178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LD127025 MF
Description: At Visit 1, one-half of the subjects will be randomized to receive the investigational soft contact lens, after approximately one week of wearing the first lens type, the subjects will return for the 1-Week Crossover Visit (Visit 2) for an exam, and to determine if the subject remains eligible to continue in the next phase of the study with the control soft contact lens.
Study NCT04006223 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 11C-PIB or 18F-florbetapir PET/MR after treatment
Description: 10-20 mCi 11C-PIB or 5-10 mCi 18F-florbetapir will be injected intravenously prior to imaging.
Study NCT03565458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin
Description: zemiglo 50mg,LG Chem
Study NCT03565458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: forxiga, dapagliflozin 10mg
Study NCT01959178 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air Optix Aqua MF
Description: At Visit 1, one-half of the subjects will be randomized to receive the control soft contact lens, after approximately one week of wearing the first lens type, the subjects will return for the 1-Week Crossover Visit (Visit 2) for an exam, and to determine if the subject remains eligible to continue in the next phase of the study with the investigational soft contact lens.
Study NCT01959178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air Optix Aqua MF
Description: At Visit 1, one-half of the subjects will be randomized to receive the control soft contact lens, after approximately one week of wearing the first lens type, the subjects will return for the 1-Week Crossover Visit (Visit 2) for an exam, and to determine if the subject remains eligible to continue in the next phase of the study with the investigational soft contact lens.
Study NCT04594135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-CD5 CAR T cells
Description: anti-CD5 CAR T cells transduced with a lentiviral vector to express CD5 chimeric receptor domain on T cells
Study NCT03121300 — intervention group
Intervention type: OTHER
Intervention: CT Scan
Description: Quantitative lung SPECT-CT
Study NCT03121300 — intervention group
Intervention type: OTHER
Intervention: Lung CT
Description: CT lung ventilation
Study NCT03121300 — intervention group
Intervention type: OTHER
Intervention: MRI
Description: DCE MRI
Study NCT03121300 — intervention group
Intervention type: OTHER
Intervention: Walk Test
Description: 6 minute hall walk test
Study NCT03121300 — intervention group
Intervention type: OTHER
Intervention: SGRQ
Description: St. George Respiratory Questionnaire
Study NCT03121300 — intervention group
Intervention type: OTHER
Intervention: Biological Sample Collection
Description: Blood Draw
Study NCT03121300 — intervention group
Intervention type: OTHER
Intervention: Toxicity
Description: Toxicity Evaluation
Study NCT03121300 — intervention group
Intervention type: OTHER
Intervention: Cardiac Assessment
Description: Cardiac MRI Scan
Study NCT01296971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc weekly
Study NCT01296971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]
Description: 1'000/1'200 mg daily orally, 24 - 72 weeks
Study NCT01296971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]
Description: 800 mg daily orally, 16 - 48 weeks
Study NCT00383669 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamins (including B, C and E)
Description: One daily oral dose of 20 mg B1, 20 mg B2, 25 mg B6, 100 mg niacin, 50 μg B12, 0.8 mg folic acid, 500 mg C, and 30 mg vitamin E taken taken from randomization until the end of follow-up (24-28 months).
Study NCT00383669 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamins B, C and E
Description: One daily oral dose of 1.2 mg vitamin B1, 1.2 mg vitamin B2, 1.3 mg vitamin B6, 15 mg niacin, 2.4 μg vitamin B12, 0.4 mg folic acid, 80 mg vitamin C, and 15 mg vitamin E taken taken from randomization until the end of follow-up (24-28 months).
Study NCT04805476 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non invasive mechanical ventilation
Description: Prophylactic non invasive mechanical ventilation
Study NCT04805476 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GP
Description: GP subjects will receive oxygen therapy through a nasal cannula with 4 to 6 L / min of oxygen according to team routine and patient need.
Study NCT01288170 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nebcinal Tobi
Study NCT01288170 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tobi Nebcinal
Study NCT00413673 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRK
Description: PRK
Study NCT02506855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Study NCT02506855 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02506855 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus Abdominis Plane Block
Study NCT02506855 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transversus Abdominis Plane Block
Study NCT03440515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone treatment for severe skin rash induced by imatinib
Study NCT02198859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Study NCT01168843 — intervention group
Intervention type: OTHER
Intervention: computerized analysis of sonographic images
Description: Evaluation of the Symmetry between the Primary Sulci of the Two Fetal Brain Hemispheres Using 3-dimensional Ultrasound Planes
Study NCT03233828 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: 500,000 IU in 0.1mL
Study NCT03233828 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.1 mL of sterile saline solution (0.9% m/v)
Study NCT01672086 — intervention group
Intervention type: DEVICE
Intervention: Stelkast Surpass Acetabular System implant
Study NCT01146184 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexible endoscope and Ethicon Manually Articulating Device
Description: Using the Flexible Endoscope and the Ethicon Manually Articulating Device, removal of the gallbladder through a single incision is improved.
Study NCT03703960 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypnotic analgesia
Description: classic three-step hypnosis procedure (induction, trance and return to consciousness).
Study NCT03703960 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: music
Description: calm music conducive to relaxation
Study NCT00853190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule
Description: Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule, single dose with food
Study NCT03565458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: jardiance 25mg, empagliflozin
Study NCT04069871 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: trans-cutaneous electrical nerve stimulation.
Description: • Patients assigned to the EMS group received daily EMS sessions of both lower extremities starting from the second day for 5days.
Study NCT04069871 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TENS
Description: Patients in the control group will receive sham TENS.
Study NCT02496936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SFA
Description: High saturated fatty acid/SFA oil source